Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults

Trial Identifier: D5290C00007
Sponsor: AstraZeneca
IQVIA RDS (Shanghai) Co., Ltd.
NCTID:: NCT04840849
Start Date: June 2021
Primary Completion Date: November 2021
Study Completion Date: November 2021

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese Translation

Trial Locations

Country Location
CN Shanghai, CN, 200040